Anti Influenza B Virus NP - Cosmo Bio Co.,Ltd.

Antibodies

>

Anti Influenza B Virus NP Antibody

Catalog No.: BAM-65-170-EX
Size: 100UG
Price: ¥34500
$460
antigen/source: Influenza B Virus NP
Storage: -20C
@
Immunogen: Influenza Virus
Clone: 8C8

Other:

 Background 
Influenza virus nucleoprotein (NP) is a major component of the ribonucleoprotein complex and is abundantly expressed during the course of infection. It is a structural protein, which encapsidates the negative strand viral RNA and isessential for RNA transcription, replication and packaging. From the nucleotide sequence, NP is consists of 560 amino acids with calculated molecular mass of 61,770.
 Application 
1) Immunofluorescent and Immunocytochemical staining (1/100 dilution)
2) Immunoprecipitation (1/100 dilution)
3) ELISA (assay dependent)
May not suitable for western blotting
 Specificity 
Reacts with NP of all Influenza B viruses so far tested (113 clinical strains), including Yamagata lineage strains; Mie/1/1993, JohanesBurg/5/1999, Florida/4/2006 and Victoria lineage strains; Lee/1940, Gif/21/1973, Shangdong/7/1997, Malasia/2506/2004, Massachustts/2/2012
No cross reactivity with influenza A viruses.



 IMAGE1



Fig.1 Immunofluorescence assay of MDCK (canine kidney ) cells infected with Influenza B virus, using anti-Influenza B virus NP antibody (clone 8C8). Samples were taken at 24 hours post-infection. Anti-Influenza B Virus NP antibody (clone 8C8) efficiently detected the viruses in the infected MDCK cells. The cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) and permeabilized with 0.1% Triton X-100 in PBS. The bound antibody was visualized by a further reaction with an Alexa Fluor 488-conjugated secondary antibody. Images on the left are mock-infected MDCK cells as negative control. The cells infected with an Influenza B virus vaccine strain, Malaysia/2506/2004 as a representative of Victoria group is shown in the upper panel and Florida/4/2006 as Yamagata group in the lower panel.

Reference:

•  Nakagawa N. et. al. , J Virol Methods. 1999;79:113-2 ICC, IP
 
>